The only FDA-licensed smallpox vaccine, ACAM2000 (Smallpox (Vaccinia) Vaccine, Live), will be acquired from Sanofi by Emergent BioSolutions under a recently announced deal. The move expands and diversifies Emergent’s portfolio of medical [Read more]
SMi Group will host this year’s Superbugs and Superdrugs USA on November 13-14, 2017 in Iselin, New Jersey. Antimicrobial resistance has sparked an urgency in the development of new drugs as the industry [Read more]
A clinical trial of an experimental vaccine to prevent infection with chikungunya virus is now enrolling healthy adult volunteers at sites in the United States. The Phase 1/2 trial, which is sponsored [Read more]
The U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), Virology Division, Pathogenesis and Immunology Branch has been tasked by the Defense Threat Reduction Agency to investigate a potential for enhanced efficacy [Read more]
The U.S. Army Medical Research and Materiel Command (USAMRMC) Special Immunizations Program (SIP) currently offers Investigational New Drug (IND) products to both military and civilian personnel at risk for pathogen and toxin exposure. [Read more]
Emergent BioSolutions Inc. held a ribbon-cutting ceremony last week on May 10 to mark the formal opening of the company’s newly expanded Center for Innovation in Advanced Development and Manufacturing (CIADM) at its Bayview Campus in Baltimore. [Read more]
When the Zika virus emerged as a global threat, the Walter Reed Army Institute of Research (WRAIR) drew on its deep expertise in protecting soldiers against malaria, Ebola and other flaviviruses, to [Read more]
Soligenix, Inc. announced today that it has been granted a Japanese patent (number 6110845) further extending protection around ThermoVax including coverage of the company’s ricin toxin vaccine candidate, RiVax. The technology is [Read more]
The Centers for Disease Control and Prevention has announced intentions to award a sole source contract to Sanofi Pasteur Biologics, LLC for the purchase of services to perform a plaque titration to [Read more]
The Biomedical Advanced Research and Development Authority (BARDA) has issued two pre-solicitation notices supporting mid- and late-phase development of medical countermeasures for Ebola Virus Disease (EVD). There are currently no vaccines or therapeutics [Read more]
© 2017 Global Biodefense